This Is IVL Amplified

Calcified arterial disease is a significant challenge affecting patients around the world — one with limited treatment options. But we’re developing a groundbreaking way to combat this dangerous disease: Pulse IVL™.

Discover Pulse IVL™
Different
Deliverable
Efficient
Easy to Use

A New Way to Combat Severe Calcified Arterial Disease

With its unique Mechanism of Action (MOA), Pulse IVL™ uses high-frequency pulsatile pressure waves to fracture arterial calcium. And through its improved deliverability and intuitive design, our innovative intravascular lithotripsy system is being developed to give healthcare providers a new tool to help patients restore blood flow.

A New Era of IVL

Discover how Pulse IVL™ is designed to enable improved deliverability and empowers physicians to treat patients more effectively and efficiently.

A Fundamentally Different MOA

Our system uses a unique MOA — converting pressurized CO2 into pulsatile energy waves at a rate of 15/second that uniformly and multi-directionally radiate along the entire length of the balloon to fracture calcium while expanding the vessel.

Learn More

Proficient from Pre-Clinical to Pivotal IDE

Developed to reduce pain, increase blood flow and improve patients’ ability to walk, Pulse IVL™ is being clinically evaluated as a new treatment option for calcified arterial disease.

Peripheral Clinical Evidence

In several pre-clinical models, Pulse IVL™ was shown to be proficient in simultaneously achieving luminal expansion while producing full-thickness calcium fractures in diseased arteries in both concentric and eccentric lesions.

Learn More

Coronary Clinical Evidence

Due to the excellent results in treating calcified lesions in peripheral clinical models, we are working to achieve these same beneficial outcomes for patients with coronary artery disease.  

Carotid Clinical Evidence 

We believe the potential treatment efficiency benefits of Pulse IVL™ may be especially meaningful in treating carotid artery disease. Plans are underway to expand our system’s capabilities into carotid clinical models.  

News

AVS Announces Positive Safety and Effectiveness Data in First 95 Patients Treated in Pulse IVL IDE Study

Nov. 5, 2025 – Principal Investigator, Dr. Chris Metzger, Interventional Cardiologist at Ballad Health in Kingsport, TN, presented the results from the prospective, single-arm

Read More
News

AVS Granted Innovation Award at ISET

AVS received the 2025 Innovation Award at the International Symposium on Endovascular Therapy (ISET), a premier annual event focused on advancements in endovascular techniques

Read More
Press Release

AVS Completes a $36M Series B Financing Ahead of IVL U.S. Commercial Launch

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™

Read More
Press Release

AVS Enrolls First Patient in U.S. Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

Read More
Press Release

AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy

Read More
News

AVS Brings New Approach to Lithotripsy: Vanguards of Health Care

In a Vanguards of Health Care podcast episode, AVS CEO, Mark Toland sits down with BI analyst Matt Henriksson for an in-depth interview to

Read More
News

Pulse IVL with Angie Volk & Sean Gilligan of AVS

Angie Volk, VP of Business Development at AVS, and Sean Gilligan, COO at AVS, recently sat down with Kyle Kruse and Richard Meiklejohn on

Read More
Press Release

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

Read More
Press Release

AVS Appoints Elizabeth Galle as Vice President of Clinical Affairs

BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™

Read More
News

Cardio Conversations: AVS Talks about Starting a Company in a Pandemic, Cracking Peripheral Plaques and More

Robert Chisena, Ph.D., our CTO and Co-Founder, recently chatted with Reed Miller on the latest edition of the Cardio Conversations, a MedTech Insight podcast, to share his thoughts on our interventional technology,

Read More

Let’s Talk.

Looking to learn more about the development program for the innovative Pulse IVL™ or about AVS?

Reach Out Today